We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cancer Screening Trial Shows Survival Rate Increases When Disease Caught Early

By MedImaging International staff writers
Posted on 13 Jun 2016
Image: The UK Lung cancer Screening trial found screening high-risk individuals can identify those individuals with early stage disease, and significantly increase their chance of long-term survival (Photo courtesy of Queen Mary University of London).
Image: The UK Lung cancer Screening trial found screening high-risk individuals can identify those individuals with early stage disease, and significantly increase their chance of long-term survival (Photo courtesy of Queen Mary University of London).
The first ever UK Lung cancer Screening trial (UKLS) has shown that identifying early stage cancer in patients with a high risk of developing the disease can increase their chance of survival for five years or longer, by 73%.

The aim of the study was to highlight the need for a screening program for high-risk groups. Part of the reason lung cancer outcomes in the UK are poor, is because around 70% of patients first present to specialist care when it is already too late for effective treatment.

The study was led by researchers from the University of Liverpool (Liverpool, UK), Liverpool Heart & Chest Hospital, Royal Brompton & Harefield Hospital, and Papworth Hospital. The researchers screened patients using a technology called Low Dose Computed Tomography (LDCT) for the randomized controlled trial.

The results of the new trial showed that the clinical outcome is greatly improved for high-risk patients identified with early stage disease. Such patients have up to a 73% better chance of survival for five years or longer. More than 80% of such patients had surgery to treat the cancer.

Dr Edward Gaynor, Clinical lead on cancer for Liverpool Clinical Commissioning Group, said: "The UKLS study is a further piece of evidence that low dose CT in high risk individuals can save lives. This is particularly relevant in Liverpool where we have one of the highest incidences and mortality rates of lung cancer and the Liverpool Clinical Commissioning Group is actively exploring how it can apply the findings in this study to the benefit of Liverpool through the Healthy Lung Project."

Related Links:
University of Liverpool

Adjustable Mobile Barrier
M-458
Pocket Fetal Doppler
CONTEC10C/CL
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Half Apron
Demi

Channels

General/Advanced Imaging

view channel
Image: Example snapshots of the photon energy density at t = 0.5, 0.7, 0.9, 1.1 nanoseconds (ns) on the y = 2.0 cm plane (Horie, S., Yajima, H., Abe, M. et al., Biomedical Engineering Letters (2026). DOI: 10.1007/s13534-026-00578-9)

AI Tool Enables Real-Time Diffuse Optical Tomography for Brain Lesion Detection

Diffuse optical tomography is a noninvasive imaging technique that uses near-infrared light to detect internal abnormalities such as cerebral hemorrhage and tumors. Its clinical utility for real-time ... Read more

Imaging IT

view channel
Image: Researchers develop a vision-language model trained on large-scale data to generate clinically relevant findings from chest computed tomography images through visual question answering (Ms. Maiko Nagao from Meijo University, Japan)

Interactive AI Tool Supports Explainable Lung Nodule Assessment

Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.